Experimental assessment of pro-lymphangiogenic growth factors in the treatment of post-surgical lymphedema following lymphadenectomy

Breast Cancer Research

Volumn 12, Issue 5, 2010, Pages

  Baker, Amy ^a,b   Kim, Harold ^b   Semple, John L ^c   Dumont, Dan ^a   Shoichet, Molly ^d   Tobbia, Dalia ^e   Johnston, Miles ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BOVINE SERUM ALBUMIN; EVANS BLUE; HYALURONIC ACID; HYALURONIDASE; IODINATED POPPYSEED OIL; IODINE 125; METHYLCELLULOSE; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; BLOOD VESSEL PERMEABILITY; CELL CULTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG MIXTURE; DRUG RELEASE; ENDOTHELIUM CELL; FEMALE; FLUOROSCOPY; INFLAMMATION; LYMPH VESSEL ENDOTHELIUM; LYMPHADENECTOMY; LYMPHANGIOGENESIS; LYMPHEDEMA; NONHUMAN; POSTOPERATIVE COMPLICATION; SHEEP; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; DRUG EFFECT; HUMAN; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH VESSEL; MASTECTOMY; REGENERATION;

ANGIOPOIETIN-2; ANIMALS; BREAST NEOPLASMS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; LYMPHEDEMA; MASTECTOMY; POSTOPERATIVE COMPLICATIONS; REGENERATION; SHEEP; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 78650924335     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2638     Document Type: Article

References (34)

1. Armer J, Stewart BR, Shook RP. 30-month post-breast cancer treatment lymphoedema. J Lymphoedema 2009, 4:14-18. 2826842, 20182653.
2. Tobbia D, Semple J, Baker A, Dumont D, Johnston M. Experimental assessment of autologous lymph node transplantation as treatment of postsurgical lymphedema. Plast Reconstr Surg 2009, 124:777-786. 10.1097/PRS.0b013e3181b03787, 19730296.
3. Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, Dakhil N, Spilman S, Goris ML, Strauss HW, Quertermous T, Alitalo K, Rockson SG. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J 2002, 16:1985-1987.
4. Yoon YS, Murayama T, Gravereaux E, Tkebuchava T, Silver M, Curry C, Wecker A, Kirchmair R, Hu CS, Kearney M, Ashare A, Jackson DG, Kubo H, Isner JM, Losordo DW. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest 2003, 111:717-725. 151891, 12618526.
5. Saaristo A, Karkkainen MJ, Alitalo K. Insights into the molecular pathogenesis and targeted treatment of lymphedema. Ann N Y Acad Sci 2002, 979:94-110. 10.1111/j.1749-6632.2002.tb04871.x, 12543720.
6. Cheung L, Han J, Beilhack A, Joshi S, Wilburn P, Dua A, An A, Rockson SG. An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. BioDrugs 2006, 20:363-370. 10.2165/00063030-200620060-00007, 17176124.
7. Tobbia D, Semple J, Baker A, Dumont D, Semple A, Johnston M. Lymphedema development and lymphatic function following lymph node excision in sheep. J Vasc Res 2009, 46:426-434. 10.1159/000194273, 19155634.
8. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996, 15:290-298. 449944, 8617204.
9. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004, 5:74-80. 10.1038/ni1013, 14634646.
10. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C, Campochiaro PA, Wiegand SJ, Yancopoulos GD. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002, 3:411-423. 10.1016/S1534-5807(02)00217-4, 12361603.
11. Gupta D, Tator CH, Shoichet MS. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 2006, 27:2370-2379. 10.1016/j.biomaterials.2005.11.015, 16325904.
12. Baumann MD, Kang CE, Stanwick JC, Wang Y, Kim H, Lapitsky Y, Shoichet MS. An injectable drug delivery platform for sustained combination therapy. J Control Release 2009, 138:205-213. 10.1016/j.jconrel.2009.05.009, 19442692.
13. Kang CE, Poon PC, Tator CH, Shoichet MS. A new paradigm for local and sustained release of therapeutic molecules to the injured spinal cord for neuroprotection and tissue repair. Tissue Eng Part A 2009, 15:595-604. 10.1089/ten.tea.2007.0349, 18991489.
14. Stern R. Devising a pathway for hyaluronan catabolism: are we there yet?. Glycobiology 2003, 13:105R-115R. 10.1093/glycob/cwg112, 14514708.
15. Stern R. Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol 2004, 83:317-325. 10.1078/0171-9335-00392, 15503855.
16. Joukov V, Kumar V, Sorsa T, Arighi E, Weich H, Saksela O, Alitalo K. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem 1998, 273:6599-6602. 10.1074/jbc.273.12.6599, 9506953.
17. Nguyen VP, Chen SH, Trinh J, Kim H, Coomber BL, Dumont DJ. Differential response of lymphatic, venous and arterial endothelial cells to angiopoietin-1 and angiopoietin-2. BMC Cell Biol 2007, 8:10. 10.1186/1471-2121-8-10, 1828055, 17341311.
18. Hadamitzky C, Pabst R. Acquired lymphedema: an urgent need for adequate animal models. Cancer Res 2008, 68:343-345. 10.1158/0008-5472.CAN-07-2454, 18199525.
19. Aboul-Enein A, Eshmawy I, Arafa MS, Abboud A. The role of lymphovenous communication in the development of postmastectomy lymphedema. Surgery 1983, 95:562-565.
20. Pain SJ, Barber RW, Ballinger JR, Solanki CK, Mortimer PS, Purushotham AD, Peters AM. Local vascular access of radioprotein injected subcutaneously in healthy subjects and patients with breast cancer-related lymphedema. J Nucl Med 2004, 45:789-796.
21. Stanton AW, Modi S, Bennett Britton TM, Purushotham AD, Peters AM, Levick JR, Mortimer PS. Lymphatic drainage in the muscle and subcutis of the arm after breast cancer treatment. Breast Cancer Res Treat 2009, 117:549-57. 10.1007/s10549-008-0259-z, 19052859.
22. Leach JB, Schmidt CE. Characterization of protein release from photocrosslinkable hyaluronic acid-polyethylene glycol hydrogel tissue engineering scaffolds. Biomaterials 2005, 26:125-135. 10.1016/j.biomaterials.2004.02.018, 15207459.
23. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001, 20:1223-1231. 10.1093/emboj/20.6.1223, 145532, 11250889.
24. Balazs EA. Medical applications of hyaluronan and its derivatives. Cosmetic and pharmaceutical applications of polymers 1991, 293-310. New York: Plenum Press, Gebelein CG, Cheng F, Yang V.
25. Ikomi F, Kawai Y, Nakayama J, Ogiwara N, Sasaki K, Mizuno R, Ohhashi T. Critical roles of VEGF-C-VEGF receptor 3 in reconnection of the collecting lymph vessels in mice. Microcirculation 2008, 15:591-603. 10.1080/10739680701815538, 18951277.
26. Tammela T, Saaristo A, Holopainen T, Lyytikkä J, Kotronen A, Pitkonen M, Abo-Ramadan U, Ylä-Herttuala S, Petrova TV, Alitalo K. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med 2007, 13:1458-1466. 10.1038/nm1689, 18059280.
27. Witte MH, Erickson R, Bernas M, Andrade M, Reiser F, Conlon W, Hoyme HE, Witte CL. Phenotypic and genotypic heterogeneity in familial Milroy lymphedema. Lymphology 1998, 31:145-155.
28. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, Ylä-Herttuala S, Alitalo K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001, 7:199-205. 10.1038/84651, 11175851.
29. Laurent TC, Fraser JR. Hyaluronan. FASEB J 1992, 6:2397-2404.
30. West DC, Kumar S. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res 1989, 183:179-196. 10.1016/0014-4827(89)90428-X, 2472284.
31. Wang HS, Hung Y, Su CH, Peng ST, Guo YJ, Lai MC, Liu CY, Hsu JW. CD44 cross-linking induces integrin-mediated adhesion and transendothelial migration in breast cancer cell line by up-regulation of LFA-1 (αLβ2) and VLA-4 (α4β1). Exp Cell Res 2005, 304:116-126. 10.1016/j.yexcr.2004.10.015, 15707579.
32. Cascone I, Napione L, Maniero F, Serini G, Bussolino F. Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. J Cell Biol 2005, 170:993-1004. 10.1083/jcb.200507082, 2171441, 16157706.
33. Ryttov N, Holm NV, Qvist N, Blichert-Toft M. Influence of adjuvant irradiation on the development of late arm lymphedema and impaired shoulder mobility after mastectomy for carcinoma of the breast. Acta Oncol 1988, 27:667-670. 10.3109/02841868809091766, 3219220.
34. Becker C, Assouad J, Riquet M, Hidden G. Postmastectomy lymphedema: long term results following microsurgical lymph node transplantation. Ann Surg 2006, 243:313-315. 10.1097/01.sla.0000201258.10304.16, 1448940, 16495693.